SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities
<p dir="ltr">Human coronaviruses, especially SARS-CoV-2, are emerging pandemic infectious diseases with high morbidity and mortality in certain group of patients. In general, SARS-CoV-2 causes symptoms ranging from the common cold to severe conditions accompanied by lung injury, acut...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , |
| منشور في: |
2020
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513513967321088 |
|---|---|
| author | Ishita Gupta (9203073) |
| author2 | Balsam Rizeq (14779402) Eyad Elkord (5396390) Semir Vranic (3353012) Ala-Eddin Al Moustafa (14153205) |
| author2_role | author author author author |
| author_facet | Ishita Gupta (9203073) Balsam Rizeq (14779402) Eyad Elkord (5396390) Semir Vranic (3353012) Ala-Eddin Al Moustafa (14153205) |
| author_role | author |
| dc.creator.none.fl_str_mv | Ishita Gupta (9203073) Balsam Rizeq (14779402) Eyad Elkord (5396390) Semir Vranic (3353012) Ala-Eddin Al Moustafa (14153205) |
| dc.date.none.fl_str_mv | 2020-08-05T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.3390/cancers12082186 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/SARS-CoV-2_Infection_and_Lung_Cancer_Potential_Therapeutic_Modalities/25879585 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Oncology and carcinogenesis COVID-19 Coronavirus SARS-CoV-2 lung cancer ACE-2 TMPRSS2 inhibitors |
| dc.title.none.fl_str_mv | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Human coronaviruses, especially SARS-CoV-2, are emerging pandemic infectious diseases with high morbidity and mortality in certain group of patients. In general, SARS-CoV-2 causes symptoms ranging from the common cold to severe conditions accompanied by lung injury, acute respiratory distress syndrome in addition to other organs’ destruction. The main impact upon SARS-CoV-2 infection is damage to alveolar and acute respiratory failure. Thus, lung cancer patients are identified as a particularly high-risk group for SARS-CoV-2 infection and its complications. On the other hand, it has been reported that SARS-CoV-2 spike (S) protein binds to angiotensin-converting enzyme 2 (ACE-2), that promotes cellular entry of this virus in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2). Today, there are no vaccines and/or effective drugs against the SARS-CoV-2 coronavirus. Thus, manipulation of key entry genes of this virus especially in lung cancer patients could be one of the best approaches to manage SARS-CoV-2 infection in this group of patients. We herein provide a comprehensive and up-to-date overview of the role of ACE-2 and TMPRSS2 genes, as key entry elements as well as therapeutic targets for SARS-CoV-2 infection, which can help to better understand the applications and capacities of various remedial approaches for infected individuals, especially those with lung cancer.</p><h2>Other Information</h2><p dir="ltr">Published in: Cancers<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/cancers12082186" target="_blank">https://dx.doi.org/10.3390/cancers12082186</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_277e06f3db8f3e3c36b42f32ebe1b891 |
| identifier_str_mv | 10.3390/cancers12082186 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25879585 |
| publishDate | 2020 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic ModalitiesIshita Gupta (9203073)Balsam Rizeq (14779402)Eyad Elkord (5396390)Semir Vranic (3353012)Ala-Eddin Al Moustafa (14153205)Biomedical and clinical sciencesCardiovascular medicine and haematologyClinical sciencesOncology and carcinogenesisCOVID-19CoronavirusSARS-CoV-2lung cancerACE-2TMPRSS2inhibitors<p dir="ltr">Human coronaviruses, especially SARS-CoV-2, are emerging pandemic infectious diseases with high morbidity and mortality in certain group of patients. In general, SARS-CoV-2 causes symptoms ranging from the common cold to severe conditions accompanied by lung injury, acute respiratory distress syndrome in addition to other organs’ destruction. The main impact upon SARS-CoV-2 infection is damage to alveolar and acute respiratory failure. Thus, lung cancer patients are identified as a particularly high-risk group for SARS-CoV-2 infection and its complications. On the other hand, it has been reported that SARS-CoV-2 spike (S) protein binds to angiotensin-converting enzyme 2 (ACE-2), that promotes cellular entry of this virus in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2). Today, there are no vaccines and/or effective drugs against the SARS-CoV-2 coronavirus. Thus, manipulation of key entry genes of this virus especially in lung cancer patients could be one of the best approaches to manage SARS-CoV-2 infection in this group of patients. We herein provide a comprehensive and up-to-date overview of the role of ACE-2 and TMPRSS2 genes, as key entry elements as well as therapeutic targets for SARS-CoV-2 infection, which can help to better understand the applications and capacities of various remedial approaches for infected individuals, especially those with lung cancer.</p><h2>Other Information</h2><p dir="ltr">Published in: Cancers<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/cancers12082186" target="_blank">https://dx.doi.org/10.3390/cancers12082186</a></p>2020-08-05T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3390/cancers12082186https://figshare.com/articles/journal_contribution/SARS-CoV-2_Infection_and_Lung_Cancer_Potential_Therapeutic_Modalities/25879585CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/258795852020-08-05T03:00:00Z |
| spellingShingle | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities Ishita Gupta (9203073) Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Oncology and carcinogenesis COVID-19 Coronavirus SARS-CoV-2 lung cancer ACE-2 TMPRSS2 inhibitors |
| status_str | publishedVersion |
| title | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
| title_full | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
| title_fullStr | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
| title_full_unstemmed | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
| title_short | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
| title_sort | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Oncology and carcinogenesis COVID-19 Coronavirus SARS-CoV-2 lung cancer ACE-2 TMPRSS2 inhibitors |